Table III.
Regional subgroup analysis: Asian vs. non-Asian countries.
| Case group | Control group | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
Random effects model OR (95% CI) | P-value (meta-regression) | I2 | P-value (Cochrane Q-test) | ||||
| Subgroups | No. of studies | Summed events | Summed total | Summed events | Summed total | ||||
| HPV (all genotypes) | |||||||||
| Asia | 12 | 202 | 422 | 32 | 176 | 4.75 (2.15–10.49) | 0.91 | 60.2 | 0.0051 |
| Non-Asia | 7 | 69 | 228 | 47 | 279 | 4.13 (0.42–40.90) | 94.2 | <0.0001 | |
| HPV 16/18 | |||||||||
| Asia | 12 | 154 | 843 | 21 | 627 | 5.12 (1.74–15.06) | 0.90 | 66.9 | 0.0013 |
| Non-Asia | 7 | 59 | 228 | 19 | 279 | 4.40 (0.52–37.19) | 88.5 | 0.0002 | |
Pooled odds ratios and 95% CIs for random effects models. HPV, human papillomavirus; HPV 16/18, HPV 16 and/or 18; OR, odds ratio.